[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postural-tachycardia-syndrome-pots\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postural-tachycardia-syndrome-pots":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100607544","phase-2-effect-of-2-hoba-in-persistent-immune-activation-in-long-covid-pots-100607544",false,"NCT07189936","Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS","Mechanism of Isolevuglandin-Protein Adduct Formation in Persistent Immune Activation in Long COVID POTS","Inclusion Criteria:\n\nAll participants should meet diagnostic criteria for Long COVID and POTS and as outlined below:\n\nLong COVID (LC) is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection.\n\nPOTS: the presence of chronic symptoms lasting more than 3 months, along with orthostatic tachycardia (a HR increase over 30 bpm upon standing or exceeding 120 bpm without orthostatic hypotension) within 10 minutes upon standing or 75-degree head up tilt.\n\nFor patients aged 18 and 21, an increase of more than 40 bpm or a standing HR over 130 bpm will be required for inclusion in the study.\n\n2 Patients need confirmation of POTS diagnosis based on orthostatic vital signs obtained prior to enrollment in the study.\n\nSARS-CoV-2 infection 3 or more months prior identified by the follow signs:\n\nA. Meets the clinical OR epidemiological criteria.\n\n1. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness\u002Ffatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia.\n2. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presents with acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization); or C. Presents with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 antigen-Rapid Diagnostic Test.\n\nD. A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or E. Meeting clinical criteria AND\u002FOR epidemiological criteria (See A). With a positive professional use or self-test, SARS-CoV-2 Antigen-Rapid Diagnostic Test.\n\nF. Documented by health care provider in clinical note or encounter.\n\nExclusion Criteria:\n\n1. Known active acute SARS-Cov-2 infection (4 weeks from onset)\n2. Moderate or severe immunocompromised patients,\n3. Known history of cardiovascular disease (atrioventricular block (AV block), myocardial infarction, angina, heart failure, pacemaker, stroke, transient ischemic attack within 6 months before enrollment),\n4. Uncontrolled hypertension (BP\\>140\u002F90 despite appropriate treatment);\n5. Type 1 or type 2 diabetes mellitus;\n6. Impaired hepatic function (AST or ALT greater than 1.5x the upper limit of normal or with total bilirubin ≥1.5mg\u002Fdl),\n7. Impaired renal function test (eGFR\\\u003C60 mL\u002Fmin\u002F1.73m2),\n8. Anemia (hemoglobin \\\u003C10 g\u002Fdl),\n9. Pregnant or breastfeeding women,\n10. Known history of autoimmune disease, steroid use or other immunotherapies,\n11. Inability to provide informed consent.\n\nWe will also exclude individuals with known allergy sensitivity to components of the study medication, known contraindication to the study interventions, use of central acetylcholinesterase inhibitors (e.g., pyridostigmine, donezepil), aspirin allergy because salicylic acid is a metabolite of 2-HOBA; use of monoamine oxidase inhibitors (MAO-I) because of some inhibition of MAO-A is present in the anticipated therapeutic range of 2-HOBA.\n\n\\-","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID.\n\nLong COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia.\n\nResearch has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte\u002FT cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection.\n\nThe purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo",[26,27,28,29],"Post-Acute COVID-19 Syndrome","Postural Tachycardia Syndrome (POTS)","SARS CoV 2 Infection","Long COVID19",[31],"Long COVID","RECRUITING","2026-01-21",{"date":35,"type":36},"2026-01-22","ACTUAL",{"date":38,"type":36},"2025-12-18",{"date":40,"type":20},"2029-06-30",{"name":42,"class":43},"Vanderbilt University Medical Center","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100471617","cardiovascular-autonomic-and-immune-mechanism-of-post-covid-19-tachycardia-syndrome-100471617","NCT05421208","Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome","Inclusion Criteria:\n\n* Prior RT-PCR-confirmed COVID-19 infection.\n* Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\\>30 bpm) and chronic (\\>3 months) pre-syncopal symptoms.\n\nExclusion criteria:\n\n* Heart Disease: Myocardial Infarction, angina, heart failure\n* History of stroke, or transient ischemic attack\n* Undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries)\n* Uncontrolled hypertension defined as persistent blood pressure \\>140\u002F90.\n* Post-menopausal women.\n* Diabetes Mellitus Type 1 or Type 2. ,\n* Impaired Hepatic function\n* Impaired renal function test (eGFR\\\u003C60 mL\u002Fmin\u002F1.73m2).\n* Ongoing substance abuse.\n* Mental conditions rendering a subject unable to understand the nature, scope and possible consequences of the study.\n* History of seizures.\n* Chronic use of steroids, NSAIDs.\n* On biologics such as anti-IL6 (omalizumab) and anti-TNF-alpha drugs\n* Pregnancy or breastfeeding",true,{"count":53,"type":20},60,[55],"NA","The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections.\n\nThis syndrome affects mostly women (\\~80%), present with chronic tachycardia and Orthostatic intolerance symptoms without any identifiable cause. In addition, non-specific symptoms such as fatigue, headache, and \"brain fog\", commonly described in POTS patients are also present in this novel condition, recently named post-COVID-19 tachycardia syndrome, POTS variant.\n\nReduced Vagal activity and unresolved inflammation is post-COVID-19 POTS is hypothesized as the cause of Long COVID",[58,27,31,28],"Post-acute COVID-19 Syndrome",[60],"SARS-CoV-2 infection","2026-01-15",{"date":63,"type":36},"2026-01-20",{"date":65,"type":36},"2022-06-01",{"date":67,"type":20},"2027-06-30",{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":44},"100468145","phase-2-splanchnic-venous-capacitance-in-postural-tachycardia-syndrome-100468145","NCT05375968","Splanchnic Venous Capacitance in Postural Tachycardia Syndrome","Mechanism of Glucose-dependent Insulinotropic Polypeptide (GIP) on Splanchnic Venous Capacitance in Postural Tachycardia Syndrome","Inclusion Criteria:\n\n* Between 18 and 50years of age\n* Cases: Diagnosis of POTS with presyncope symptoms after meals Or\n\nControls:\n\n* With no significant past medical history, non-smokers and not on chronic medications.\n* Body mass index (BMI) between 18.5 to 29.9 kg\u002Fm2\n* If pre-menopausal women: must have regular menstrual cycle.\n\nExclusion Criteria:\n\n* BMI above ≥30 kg\u002Fm2\n* Irregular menstrual cycle\n* Intolerance to CPAP.\n* Chronic use of acetaminophen\n* Heart problems: myocardial infarction, angina, heart failure, stroke\n* Undergone any heart related procedures or stents or on pacemaker.\n* Uncontrolled hypertension.\n* Type 1 or type 2 diabetes mellitus\n* Pregnant or breast-feeding women.\n* Impaired liver function\n* Impaired Kidney function test.\n* Anemia (Hematocrit\\\u003C34%).\n* Ongoing substance abuse.\n* Subjects with abnormal EKG\n* History of seizures.\n* Diagnosed with neuropathy due to any reason\n* History of neck surgery.\n* Smoker,\n* On statin therapy for high cholesterol\n* Rheumatoid arthritis.\n* On oral corticosteroids,\n* Current infections\n* Documented of moderate decrease in blood volume","50 Years",{"count":19,"type":20},[23],"Postural tachycardia syndrome (POTS) affects ≈3 million young people, characterized by chronic presyncopal symptoms characterized by dizziness, lightheadedness, and orthostatic tachycardia that occur while standing. Across-sectional survey found that 25% of these patients complains that meals rich in carbohydrates are among the factors that further exacerbate POTS's symptoms and cause a myriad of gastrointestinal symptoms.\n\nThe splanchnic circulation is the largest blood volume reservoir of the human body, storing ≈25% of the total blood volume and contributing to sudden, and large, fluctuations in the stroke volume (SV). The orthostatic changes in systemic hemodynamics are particularly magnified after meals, due to increased blood volume sequestration triggered by the release of gastrointestinal peptides with vasodilatory properties. The purpose of this study is to determine if the worsening orthostatic tachycardia and symptoms after glucose ingestion in POTS patients are due to a greater increase in splanchnic venous capacitance and excessive blood pooling on standing as compare to Healthy controls.\n\nThe study will also determine if glucose-induced GIP secretion increases splanchnic venous capacitance, orthostatic tachycardia and worsening POTS postprandial symptoms. For this purpose subjects will be further randomized to either saline versus GIP(3-30)NH2 acute infusion, to measure the changes their splanchnic venous capacitance and superior mesenteric arterial flow before and after a 75-g oral glucose challenge during supine and 45-degree head-up tilt positions (orthostatic challenge) for up to 3 hours.",[27],[82],"Glucose-dependent Insulinotropic Polypeptide (GIP)","2025-12-04",{"date":85,"type":36},"2025-12-05",{"date":87,"type":36},"2023-02-25",{"date":89,"type":20},"2028-06-01",{"name":42,"class":43}]